Share This Page
Drug Price Trends for NDC 13811-0582
✉ Email this page to a colleague
Average Pharmacy Cost for 13811-0582
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13811-0582
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 13811-0582
Introduction
The drug identified by NDC 13811-0582 is Kuvan® (sapropterin dihydrochloride), a pharmaceutical indicated for the treatment of phenylketonuria (PKU), a rare inherited metabolic disorder. As a targeted therapy, Kuvan plays a pivotal role within the niche metabolic medications market, which is characterized by high unmet medical needs and specialized patient populations. Understanding the current and projected market landscape involves examining factors such as clinical efficacy, competitive landscape, pricing trends, regulatory environment, and evolving reimbursement policies.
Market Overview
Therapeutic Profile and Clinical Demand
Kuvan (sapropterin dihydrochloride) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor involved in phenylalanine metabolism. PKU patients experience elevated phenylalanine levels due to deficient phenylalanine hydroxylase enzyme activity. Kuvan reduces phenylalanine levels, enabling improved neurological outcomes and quality of life.
Clinical adoption of Kuvan peaked after FDA approval in 2007 and was further expanded with indications for various age groups and genetic variants. The demand remains steady among diagnosed PKU patients, estimated at approximately 20,000 globally, with a significant proportion in North America and Europe.
Market Size and Growth Potential
The global PKU market is relatively niche, with the US market accounting for the majority of sales due to high diagnosis rates and advanced healthcare infrastructure. According to IQVIA data, the US PKU drug market generated approximately $300-$350 million in sales annually pre-pandemic. With increasing awareness and early diagnosis, the patient population may grow modestly.
Emerging therapies, including gene therapy candidates and enzyme substitution approaches, could introduce competitive dynamics but are still in experimental stages. Kuvan is expected to maintain a prominent position as the first-line pharmacotherapy.
Market Drivers and Constraints
Drivers
- Increased diagnosis of PKU through newborn screening programs is expanding the treated patient base.
- Expanded indications and favorable efficacy profile bolster longer-term patient adherence.
- Reimbursement developments tend to favor established therapies like Kuvan due to proven safety and clinical benefit.
Constraints
- High treatment cost—the average annual cost per patient exceeds $150,000, constraining accessibility and reimbursement.
- Competitive landscape: Emerging therapies, like pegvaliase (an enzyme substitution therapy approved for adults), threaten to redefine treatment paradigms.
- Limited patient population influences pricing strategies and market penetration.
Competitive Landscape
Key competitors include:
- Pegvaliase (Palynziq®): Approved in 2018 for adults with PKU; offers a different mechanism—enzyme substitution—and may replace Kuvan for some patients.
- Dietary management: Low-phenylalanine diets remain foundational but are less efficacious and patient-friendly.
The market strategy involves positioning Kuvan as the initial pharmacologic intervention, especially pre-dietary therapy failure, with alternate treatments like pegvaliase reserved for refractory cases.
Pricing Trends and Projections
Current Pricing Dynamics
The average annual cost for Kuvan in the US ranges between $150,000 and $180,000 per patient, influenced by dosing regimens based on body weight or phenylalanine levels. The pricing strategy reflects:
- High specificity for its indication;
- Market exclusivity granted by patent protections and regulatory exclusivity periods;
- Manufacturing complexities inherent to biologics.
Price Trends (Past 3-5 Years)
- Stable pricing with minimal fluctuation owing to the limited competition and high clinical value.
- Patent protections expiring in the late 2020s or early 2030s could facilitate biosimilar entry, leading to potential price erosion.
- Reimbursement pressures and value-based pricing models are emerging, potentially influencing future pricing.
Projected Price Evolution
Over the next five years, Kuvan's price is expected to remain relatively stable in the absence of biosimilar competition. However, with the imminent expiration of its patent exclusivity:
- Biosimilar development could reduce prices by 20–40%, akin to observed biologic markets.
- Market entry of biosimilars may be delayed due to regulatory and commercial barriers, but competition is inevitable, likely by 2028–2030.
- Reimbursement trends might shift towards value-based agreements, influencing effective patient costs.
In the longer term, if biosimilar versions enter, price reductions of 30%–50% could ensue, making treatment more accessible but impacting revenue streams.
Regulatory and Reimbursement Outlook
Regulatory Environment
The FDA grants orphan drug designation, providing seven-year market exclusivity, which extends patent protections. Pending biosimilar approvals, market entry could be delayed beyond patent expiry.
Reimbursement Landscape
Insurance coverage for Kuvan is generally favorable, given FDA approval and clinical efficacy, but payer negotiations may lead to value-based agreements, influencing pricing strategies.
Conclusion and Strategic Implications
Kuvan remains a high-value asset within the PKU market, supported by strong clinical evidence and regulatory exclusivity. Its pricing has historically been stable, but impending patent expiration and biosimilar entry will introduce downward price pressures. Pharmaceutical companies should closely monitor biosimilar developments, reimbursement trends, and evolving standards of care to optimize market positioning and maximize revenue.
Key Takeaways
- Kuvan (NDC 13811-0582) holds a dominant position in the PKU pharmacotherapy landscape, with stable pricing due to regulatory exclusivity and clinical demand.
- Market growth is moderate, driven by increased diagnosis and awareness, but long-term growth may be constrained by high treatment costs.
- Biosimilar entrants expected by late 2020s or early 2030s could lead to significant price reductions, impacting profitability.
- Reimbursement strategies and value-based models are becoming increasingly influential in shaping pricing and market access.
- Strategic planning should factor in patent expiration timelines, biosimilar regulatory pathways, and competitive landscape shifts.
FAQs
1. When will biosimilar versions of Kuvan likely enter the market?
Biosimilar development timelines suggest entry could occur around 2028–2030, contingent upon patent expiry and regulatory approvals.
2. How does the pricing of Kuvan compare internationally?
Outside the US, Kuvan is often priced lower due to different healthcare reimbursement systems and negotiated discounts, though exact figures vary by country and insurer.
3. What are the primary factors influencing Kuvan's future price?
Patent expiration, biosimilar competition, clinical adoption, reimbursement policies, and manufacturing costs.
4. Are there bioequivalent alternatives to Kuvan currently available?
No direct biosimilar exists yet, but pegvaliase offers an alternative approach for certain patient groups, potentially affecting Kuvan’s market share.
5. How might emerging gene therapies impact Kuvan's market?
Gene therapy candidates for PKU are in early development and could offer curative potential, possibly replacing chronic pharmacotherapy like Kuvan if proven safe and effective.
References
[1] IQVIA. US Specialty and Biologic Market Data. 2022.
[2] Food and Drug Administration. FDA Approvals for PKU Treatments. 2018–2022.
[3] Market Research Future. Global PKU Treatment Market Analysis. 2021.
[4] Pharmaceutical Commerce. Biosimilar Entry and Impact on Biologic Pricing. 2022.
More… ↓
